YJEFN3 (YjeF N-terminal domain-containing protein 3) has been identified as a tumor-associated antigen in prostate adenocarcinoma (PRAD), where its overexpression and mutations are linked to poor prognosis and altered immune cell infiltration (55). This evidence concerns the gene YJEFN3 and prostate adenocarcinoma.